Stock Analysis on Net

Bristol-Myers Squibb Co. (NYSE:BMY)

Balance Sheet: Assets
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Bristol-Myers Squibb Co., consolidated balance sheet: assets (quarterly data)

US$ in millions

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Cash and cash equivalents 11,464 7,514 8,372 8,995 9,123 7,734 10,750 12,369 13,979 13,540 11,024 10,982 14,546 19,435 19,934 15,817 12,346 30,489 28,404 7,335
Marketable debt securities 816 171 358 274 130 1,293 2,478 2,599 2,987 2,123 1,946 1,948 1,285 1,720 1,724 2,505 3,047 2,053 953 1,429
Receivables 10,921 10,304 10,112 10,054 9,886 9,613 9,054 8,511 9,369 9,245 9,017 8,660 8,501 8,062 7,855 8,290 7,685 5,510 5,667 5,704
Inventories 2,662 2,436 2,364 2,605 2,339 2,074 2,142 2,104 2,095 2,163 2,137 1,953 2,074 1,949 2,384 2,836 4,293 1,192 1,308 1,283
Other current assets 5,907 7,207 6,868 5,158 5,795 6,082 5,762 4,538 4,832 4,372 5,037 3,568 3,786 3,111 2,446 2,405 1,983 947 1,384 1,342
Current assets 31,770 27,632 28,074 27,086 27,273 26,796 30,186 30,121 33,262 31,443 29,161 27,111 30,192 34,277 34,343 31,853 29,354 40,191 37,716 17,093
Property, plant and equipment 6,646 6,481 6,355 6,279 6,255 6,035 5,970 6,047 6,049 5,868 5,795 5,763 5,886 5,740 5,777 6,112 6,252 4,830 4,849 4,985
Goodwill 21,169 21,147 21,163 21,162 21,149 21,112 20,446 20,500 20,502 20,519 20,529 20,524 20,547 20,517 20,578 22,452 22,488 6,513 6,533 6,536
Other intangible assets 27,072 28,950 31,303 33,569 35,859 38,179 37,690 40,103 42,527 44,930 48,065 50,819 53,243 56,698 59,171 61,666 63,969 1,002 995 1,026
Deferred income taxes 2,768 1,514 1,572 1,317 1,344 1,329 1,337 1,418 1,439 684 650 793 1,161 913 1,088 605 510 1,624 1,442 1,380
Marketable debt securities 364 325 46 143 288 433 495 523 651 767 925 994 1,233
Other non-current assets 5,370 5,214 5,022 4,868 4,940 4,745 4,728 4,845 5,535 7,403 6,454 7,137 7,019 6,896 6,596 5,946 6,604 2,348 2,634 2,581
Non-current assets 63,389 63,631 65,415 67,195 69,547 71,400 70,171 72,913 76,052 79,450 81,636 85,324 88,289 91,259 93,733 97,432 100,590 17,242 17,447 17,741
Total assets 95,159 91,263 93,489 94,281 96,820 98,196 100,357 103,034 109,314 110,893 110,797 112,435 118,481 125,536 128,076 129,285 129,944 57,433 55,163 34,834

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).


Assets: Selected Items

Balance sheet item Description The company
Current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Bristol-Myers Squibb Co. current assets decreased from Q2 2023 to Q3 2023 but then increased from Q3 2023 to Q4 2023 exceeding Q2 2023 level.
Property, plant and equipment Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Bristol-Myers Squibb Co. property, plant and equipment increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Non-current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Bristol-Myers Squibb Co. non-current assets decreased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Total assets Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Bristol-Myers Squibb Co. total assets decreased from Q2 2023 to Q3 2023 but then increased from Q3 2023 to Q4 2023 exceeding Q2 2023 level.

Current Assets: Selected Items

Balance sheet item Description The company
Cash and cash equivalents Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Bristol-Myers Squibb Co. cash and cash equivalents decreased from Q2 2023 to Q3 2023 but then increased from Q3 2023 to Q4 2023 exceeding Q2 2023 level.
Marketable debt securities Amount of investment in marketable security, classified as current. Bristol-Myers Squibb Co. marketable debt securities decreased from Q2 2023 to Q3 2023 but then increased from Q3 2023 to Q4 2023 exceeding Q2 2023 level.
Inventories Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. Bristol-Myers Squibb Co. inventories increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.